Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment of Postural and Gait Dysfunction in Parkinson's Disease

Clinical Trial Title: 
Varenicline (Chantix) for the treatment of postural and gait dysfunction in Parkinson's disease
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Deborah A. Hall, MD
Clinical Trial Protocol Description: 

The purpose of this study is to test the drug Chantix on patients with Parkinson's disease and to see if it can improve balance impairment and postural instability often found in that patient population. This is a single-center, placebo-conrolled study, and we expect to recruit approximately 40 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have mild to moderate Parkinson’s disease with a history of falls.
  • Are at least 40 years of age.

You will be excluded from the study if any of the following criteria apply to you:

  • Have current psychiatric disease.
  • Are currently a smoker or taking nicotine replacement products.
  • Are currently taking Artane, Cogentin or Wellbutrin.
  • Have severe tremor.

This is a partial list of eligibility requirements. 

Clinical Trial Area: 
Parkinson's Disease and Other Movement Disorders
Contact Phone: 
(312) 563-2900 ext. 4
Contact Name: 
Deborah A. Hall, MD